Terlipressin Administration in Septic Shock Refractory to Catecholamines
- Registration Number
- NCT00793559
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Brief Summary
terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in Israel and Europe. It is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in BP and heart function
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- septic shock patients receiving above 0.5 mcg/kg NA
Exclusion Criteria
- allergy to terlipressin, CHF, IHD, pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description terlipressin bolus terlipressin 1 mg of terlipressin received one time only terlipressin drip terlipressin -
- Primary Outcome Measures
Name Time Method CI, SVR,HR,BP, noradrenalin administration,renal function 6 mo
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie terlipressin's hemodynamic effects in catecholamine-resistant septic shock?
How does continuous terlipressin infusion compare to bolus administration in maintaining MAP in NCT00793559?
Which biomarkers correlate with improved outcomes in septic shock patients treated with vasopressin analogs like terlipressin?
What are the cardiovascular adverse events associated with terlipressin in NCT00793559 and how are they managed?
How does terlipressin's efficacy in septic shock compare to other vasoactive agents like vasopressin or norepinephrine?
Trial Locations
- Locations (1)
Asaf Harofeh MC
🇮🇱Zrifin, Israel
Asaf Harofeh MC🇮🇱Zrifin, Israel